Hepcludex is now the first and only approved treatment for HDV patients in the US, marking a significant milestone for the HDV market.
Hansa Biopharma’s Idefrix (imlifidase) has seen a 90% one-year survival from GvHD in patients following a kidney transplant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results